Financings

Allakos Inc. completed a $100 million series B round.

Argenx NV priced its public offering of American depositary shares for gross proceeds of about $231 million.

Bellus Health Inc. closed its equity offering for gross proceeds of C$20 million.

Bluebird Bio Inc. priced an underwritten public offering for anticipated total gross proceeds of approximately $600 million.

Blueprint Medicines Corp. priced an underwritten public offering with proceeds expected to total about $300 million.

Denali Therapeutics Inc. closed its IPO of 15.97 million shares of its common stock at $18 each.

Dicerna Pharmaceuticals Inc. priced its public offering for gross proceeds of about $40 million.

Fennec Pharmaceuticals Inc. priced an underwritten public offering for gross proceeds of about $20 million.

Hookipa Biotech AG has raised €50 million (US$59 million) in an oversubscribed series C round.

Kyn Therapeutics Inc. said it raised $49 million in a series A round.

Northsea Therapeutics BV has completed a €25 million (US$29.4 million) series A funding round.

Odonate Therapeutics Inc. said it closed its IPO of 6.25 million shares at $24 each for gross proceeds of about $150 million.

Pionyr Immunotherapeutics Inc. raised $62 million from a series B round.

Revance Therapeutics Inc. closed its public offering for gross proceeds $167.1 million.

Viking Therapeutics Inc. closed its public offering for gross proceeds of about $14.8 million.

Deals

Aprecia Pharmaceuticals Co. and Cycle Pharmaceuticals Ltd. have cemented a deal to develop and commercialize orphan drugs through three-dimensionally printed technology.

Cyclenium Pharma Inc. signed a drug discovery agreement with Ono Pharmaceutical Co. Ltd., which will focus on Cyclenium's Quest Library of synthetic small-molecule macrocycles and related expertise to identify clinical candidates for development in multiple pharmacological targets.

Daiichi Sankyo Co. Ltd. and Puma Biotechnology Inc. entered a preclinical research collaboration with Memorial Sloan Kettering Cancer Center to explore the combination of Daiichi's investigational antibody-drug conjugate, DS-8201, and Puma's irreversible pan-HER tyrosine kinase inhibitor, Nerlynx (neratinib), in HER2-mutated or HER2-positive solid tumors.

Evotec AG entered a research collaboration with the Center for Regenerative Therapies at Technische Universität Dresden to discover new small-molecule candidates for retinal diseases.

Gilead Sciences Inc. has acquired Cell Design Labs Inc., which has focused on reengineering the molecular machinery of human cells – specifically, to fight cancer.

Palleon Pharmaceuticals Inc. signed an agreement with King's College London giving the firm exclusive rights to a patent portfolio that will facilitate the development of drugs that target glycoimmune checkpoints.

Repros Therapeutics Inc. entered a definitive agreement under which Allergan plc, through a subsidiary, will acquire the company for a cash payment of 67 cents per share.

X-Chem Inc. and Abilita Bio Inc. entered a joint research collaboration to discover modulators of high-value G protein-coupled receptor and ion channel targets.

. . . And More

Alnylam Pharmaceuticals Inc. completed the rolling submission of a new drug application to the FDA for patisiran, an RNAi therapeutic targeting transthyretin being studied to treat adults with hereditary transthyretin-mediated amyloidosis.

Clementia Pharmaceuticals Inc. is moving palovarotene, its lead candidate, into a registrational phase III trial testing its ability to treat fibrodysplasia ossificans progressiva, an ultra-rare bone disorder.

Erytech Pharma SA's lead candidate, Graspa (eryaspase), and low-dose cytarabine (LDAC) failed to help people with acute myeloid leukemia (AML) live longer than treatment with LDAC alone. In light of the phase IIb outcome, the company will quit AML development for Graspa, but said it remains committed to developing it for the treatment of acute lymphoblastic leukemia and pancreatic cancer.

Medimetriks Pharmaceuticals Inc. said the FDA approved Xepi (ozenoxacin) cream, 1 percent, a new chemical entity for the treatment of impetigo in patients 2 months of age and older when applied topically twice daily for five days.

Psioxus Therapeutics Ltd. has received approval for a phase I trial of NG-348, the first of its gene therapy for tumor products, triggering a $15 million milestone from partner Bristol-Myers Squibb Co.

Sirnaomics Inc. said the FDA granted orphan drug designation to its lead candidate, STP-705, for the treatment of cholangiocarcinoma.

Teva Pharmaceutical Industries Ltd. disclosed its long-awaited plan to restructure operations and reduce its crushing debt, revealing that it will eliminate more than 25 percent of its work force and seek to slash $3 billion in net costs from its bottom line by year-end 2019.